Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hit Collaterally By Popular Backlash Following Vaccine Scandals, China's Sinovac Could Exploit High Quality Standards To Emerge As Winner

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Despite being hit by a succession of vaccine scandals and resulting public fears of domestically produced biologics, China's leading vaccine developer could ultimately emerge as a more powerful player due to its sterling reputation in a field of tarnished competitors

You may also be interested in...



China Drug Safety Remains Front and Center In Chromium Capsule Scandal

China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.

China Drug Safety Remains Front And Center In Chromium Capsule Scandal

China’s latest product safety scandal could have far-reaching implications, potentially even disrupting China's tendering system for essential medicines.

Leading Chinese Vaccine Developer Sinovac Conducts Technical Exchanges With Gates Foundation On Rotavirus Vaccine

BEIJING - China's leading vaccine developer, Sinovac Biotech, is applying for Chinese regulatory approval to launch clinical trials for two new pneumococcal polysaccharides vaccines

Related Content

Latest News
UsernamePublicRestriction

Register

SC075416

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel